These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 18583085

  • 1. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
    Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG.
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
    [Abstract] [Full Text] [Related]

  • 2. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M.
    Dtsch Med Wochenschr; 2003 May 09; 128(19):1071. PubMed ID: 12736860
    [No Abstract] [Full Text] [Related]

  • 3. [New quinolones for the treatment of community-acquired pneumonia--pro].
    Zimmerli S.
    Dtsch Med Wochenschr; 2003 May 09; 128(19):1070. PubMed ID: 12736859
    [No Abstract] [Full Text] [Related]

  • 4. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.
    Jacobs MR.
    Clin Infect Dis; 2002 Sep 01; 35(5):565-9. PubMed ID: 12173130
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2004 Nov 01; 24(5):479-84. PubMed ID: 15519481
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B, Sánchez-Alvarez J, García-Mendez E, Sabriá M, Santos J, Pallarés R, Twynholm M, Dal-Ré R, 620 Clinical Study Group.
    J Antimicrob Chemother; 2006 Mar 01; 57(3):536-45. PubMed ID: 16446376
    [Abstract] [Full Text] [Related]

  • 8. Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
    Lee WK, Young BW.
    J Antimicrob Chemother; 2005 Sep 01; 56(3):603-5. PubMed ID: 16040621
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Current use of penicillin in community-acquired pneumococcal pneumonias].
    Gaztelurrutia L, Zalacaín R, Rubio G, Hernández JL, Urra E, Hernández M, Garea C, Barrón J.
    Enferm Infecc Microbiol Clin; 1994 Jan 01; 12(1):17-20. PubMed ID: 8155749
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
    Gilbert DN.
    Clin Infect Dis; 2008 Dec 01; 47 Suppl 3():S121-2. PubMed ID: 18986276
    [Abstract] [Full Text] [Related]

  • 17. What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.
    File TM, Schentag JJ.
    Clin Infect Dis; 2008 Dec 01; 47 Suppl 3():S157-65. PubMed ID: 18986283
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: analysis using current breakpoints and fluoroquinolone pharmacodynamics.
    Feldman C, Brink AJ, von Gottberg A, Wolter N, de Gouveia L, Perovic O, Klugman KP.
    Int J Antimicrob Agents; 2010 Jul 01; 36(1):95-7. PubMed ID: 20378315
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antimicrobial resistance and treatment of community-acquired pneumonia.
    Mandell LA.
    Clin Chest Med; 2005 Mar 01; 26(1):57-64. PubMed ID: 15802166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.